Insilico Medicine (HKEX: 3696) has nominated ISM9077 as a preclinical candidate (PCC) for the treatment of ocular diseases, inflammatory disorders, and aging-related conditions. Announced on Aug. 5, 2026, from Cambridge, Mass., the designation marks the company’s 32nd PCC since 2021, highlighting the scalability of its generative artificial intelligence (AI) platform in drug discovery. ISM9077 is a potential first-in-class Target Y inhibitor designed to address unmet needs in dry Age-Related Macular Degeneration (dry AMD), uveitis, and dry eye disease while offering broader therapeutic potential for aging and chronic inflammation.

The nomination follows extensive preclinical evaluation where ISM9077 demonstrated robust efficacy across multiple disease models. In dry AMD studies, the compound improved retinal structural integrity and visual function, showing efficacy approximately three times that of currently available therapies. In uveitis models, it reduced ocular inflammation and restored retinal function, while in dry eye disease trials, it outperformed Cyclosporine A (CsA), the current standard-of-care, by improving tear production and suppressing corneal inflammation. These results validate Target Y as a key therapeutic target for degenerative and inflammatory ocular conditions.

ISM9077 was developed using Chemistry42, Insilico’s integrated generative chemistry platform, which enabled de novo design based on structure-based drug design (SBDD) principles. The AI-driven process optimized pharmacophore fit, drug-likeness, and structural novelty, resulting in a molecule with low patent risk and crystallographic validation. The compound exhibits favorable oral bioavailability, low-to-moderate in vivo clearance, and retinal exposure levels 2 to 5.5 times higher than plasma levels. Its good permeability supports potential development as both an oral medication and a non-invasive eye drop formulation.

Market Context and Strategic Impact

The global market for ocular diseases exceeded USD 40 billion in 2025 and is projected to reach USD 71.58 billion by 2034. Uveitis alone accounts for more than 10% of severe visual handicaps in the United States, underscoring the need for innovative treatments with better bioavailability and safety profiles. ISM9077’s dual-purpose strategy aims to treat specific diseases while targeting the fundamental aging process, as Target Y is strongly implicated in longevity and age-related conditions.

What the Numbers Show

Insilico Medicine’s ability to nominate 32 PCCs since 2021, with 13 receiving IND approval or clearance, demonstrates a significant acceleration in early-stage drug discovery compared to industry norms. While traditional discovery typically takes 2.5 to 4 years, Insilico achieves PCC nomination in an average of 12 to 18 months by synthesizing and testing only 60 to 200 molecules per program. This efficiency reduces upfront R&D costs and time-to-market, providing a competitive advantage in addressing high-burden conditions like dry AMD and inflammatory disorders.

Alex Zhavoronkov, PhD, Founder, CEO and CBO of Insilico Medicine, stated that ISM9077 exemplifies how generative AI delivers at scale, featuring a moderately novel target and a novel molecule designed from scratch. Feng Ren, PhD, Co-CEO and CSO, noted that the compound overcomes limitations of current solutions regarding toxicity management and dosing adherence, offering a highly effective option for millions of patients suffering from blinding ocular diseases. The company continues to enhance its AI platform through MMAI Gym, partnering with Human Longevity and Liquid AI to advance pharma superintelligence.

Insilico Medicine has projected a swing to profitability for the first half of 2026, driven by a surge in revenue from lucrative partnerships with global pharmaceutical giants. The company forecast revenue between $102.5 million and $106.5 million for the period, a rise of more than 270% from the same period a year earlier. This growth is expected to turn a net loss of $19.2 million in the first half of 2025 into a projected net profit ranging from $33.5 million to $39.5 million. The profit alert comes six months after the firm completed Hong Kong's biggest IPO of 2025.

The primary driver for this financial turnaround is a series of licensing and collaboration agreements focused on cancer, lung disease, and autoimmune conditions. According to the DXY Insight database, Insilico has secured 14 deals in 2026 with a total potential value exceeding $7 billion. Key agreements include a $2.75 billion global R&D collaboration with Eli Lilly (NYSE: LLY) in March, a $2.5 billion pact with SK Biopharmaceuticals in June, and a $600 million global strategic collaboration with Takeda (NYSE: TAK) in early July. The company also signed an agreement worth up to $888 million with French drug firm Servier in January.

Strategic Alliance with Bora

Separately, Insilico and Bora Pharmaceuticals announced a strategic alliance on July 14, 2026, to combine AI-driven drug discovery with global development and manufacturing capabilities. The collaboration aims to pioneer a next-generation drug innovation model with a potential value exceeding US$2.5 billion. The partnership integrates Insilico's proprietary Pharma.AI platform with Bora's global development, manufacturing, and commercialization capabilities. Insilico expects to support Bora in strengthening AI capabilities across its global workforce.

Clinical Pipeline Progress

Beyond partnerships, Insilico is advancing its own drug pipeline. Its most advanced candidate, Rentosertib (ISM001-055), entered Phase Three trials on July 8 as a treatment for idiopathic pulmonary fibrosis. It is billed as the world's first drug where both the biological target and the therapeutic compound were discovered and designed using generative AI. While the drug has received "orphan drug" designation in the U.S. and breakthrough therapy status in China, substantive results are not expected before late 2027. The Phase Three trial is expected to wrap up at the end of June 2027, with key results likely emerging by the end of that year.

Financial Context

The company's revenue stream is inherently volatile, dependent on milestone payments and royalties. In the absence of major licensing deals last year, revenue fell to $56.24 million in 2025 from $85.83 million in 2024, while the annual net loss swelled to $352 million from $17.10 million. Insilico currently commands a market value of approximately HK$26.5 billion ($3.38 billion).